Adventist Health System changing name to AdventHealth

One of the nation’s largest faith-based health systems, Adventist Health System, will soon change its name to AdventHealth. The healthcare system will adopt the new name on Jan. 2, 2019.

Adventist, based in Altamonte Springs, Florida, has nearly 50 hospital campuses and more than 80,000 employees.

“We are transforming to be a more consumer-focused health care system to better meet the needs of those we care for and the communities we serve,” Terry Shaw, president and CEO for Adventist Health System, said in a statement. “Becoming AdventHealth allows us to be a fully integrated and distinguishable health system across all aspects of the care continuum, while also speaking to our Christian healing ministry, message of wholeness and our rich Seventh-day Adventist roots.”

The organization spent eight months preparing for the system-wide rebrand and will launch a television and print ad campaign to announce its transition in September. Joint venture locations will not change under the rebrand.

“We want our hospitals and care sites to be places where people can experience hope as well as healing, and the AdventHealth name so appropriately expresses that sense of expectation and optimism while also connecting with our promise of wholeness and our rich faith-based heritage,” Gary Thurber, board chairman for Adventist Health System, said in a statement.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.